Abstract
This cost-of-illness analysis based on information from 921 patients in Italy is part of a Europe-wide cost-of-illness study in multiple sclerosis (MS). The objective was to analyze the costs and quality of life (QOL) related to the level of disease severity and progression. Patients registered with the Italian MS patient organization were asked to participate in a mail survey, and 31% responded. The questionnaire asked for details on the disease (type of disease, relapses, level of functional disability), information on all medical and non-medical resource consumption, and informal care and work capacity (sick leave and early retirement). In addition, patients were asked about their current QOL (in the form of utility) and the level of fatigue. The mean age of respondents was 46 years, and 8.5% were 65 years or older. As many as 20% of patients had severe disease (Expanded Disability Status Scale [EDSS] score of ≥7), 47% had moderate disease (EDSS score of 4–6.5) and only 31% had mild disease (EDSS score of 0–3). Thus, the mean EDSS score in the sample was 4.6 (median 5.0), with a utility of 0.53 (range: 0 = death to 1 = full health) and a fatigue level of 6.4 (range: 1 = not tired to 10 = extremely tired). Costs and utility are highly correlated with disease severity. Workforce participation decreases from approximately 80% in early disease to less than 10% in the very late stages. Total costs increase fivefold between an EDSS score of 0–1 and a score of 7. Health-care costs, however, show a limited increase with worsening disease – hospitalization increases from € 800 per patient to € 3200, and ambulatory care increases from € 900 to € 1500. Productivity losses, on the other hand, increase by a factor of 12, while informal care increases from € 500 at an EDSS score of 0–1 to nearly € 25 000 at an EDSS score of 7, and € 39 000 at an EDSS score of 8–9. Hence, total mean costs per patient are determined essentially by the distribution of the severity levels in the sample, increasing from € 12 000 at an EDSS score of 0–1 to € 57 000 at an EDSS score of 7, and € 71 000 at an EDSS score of 8–9. The same is true for utility, which decreases from 0.80 to 0.06 as the disease becomes severe. However, the utility loss compared to the age- and gender-matched general population is high at all levels of the disease, leading to an estimated annual loss of 0.3 quality-adjusted life year (QALY) per patient. Relapses for patients with an EDSS score of <5 are associated with a cost of approximately € 4000 and a utility loss of 0.18 during the quarter in which they occur.
Similar content being viewed by others
References
Kobelt G, Berg J, Lindgren P, Fredrikson S, Jönsson B (2006) Costs and quality of life of multiple sclerosis in Europe. J Neurol. Published online April 2006
Dean G (1994) How many people in the world have multiple sclerosis? Neuroepidemiology 13: 107
Rosati G (2001) The prevalence of multiple sclerosis in the world: an update. Neurol Sci 22: 117–139
Pugliatti M, Rosati R, Carton H et al. (2006) The prevalence and incidence of multiple sclerosis in Europe. Eur J Neurol 13: 1–23
Kurtzke J (1983) Rating neurological impairment in multiple sclerosis and expanded disability status scale (EDSS). Neurology 33: 1444–1452
The EuroQol Group (1990) EuroQol – a new facility for the measurement of health-related quality of life. Health Policy 16: 199–208
Dolan P (1995) A social tariff for EuroQol: results from a UK general population survey. Centre for Health Economics, University of York: York
Henriksson F, Fredrikson S, Masterman T, Jönsson B (2001) Costs, quality of life and disease severity in multiple sclerosis. A cross-sectional study in Sweden. Eur J Neurol 8: 27–35
Kobelt G, Lindgren P, Smala A, Jönsson B (2000) Costs and quality of life in multiple sclerosis. A cross-sectional observational study in Germany. SEE/EFI Working Paper Series in Economics and Finance No. 398. Stockholm School of Economics; Stockholm, Sweden (www.hhs.se)
Kobelt G, Lindgren P, Parkin D, Jönsson B (2000) Costs and quality of life in multiple sclerosis. A cross-sectional observational study in the United Kingdom. SEE/EFI Working Paper Series in Economics and Finance No. 399. Stockholm School of Economics; Stockholm, Sweden. (www.hhs.se)
Eichler H, Kong S, Gerth W et al. (2004) Use of cost-effectiveness analysis in health care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Val Health 7: 518–528
Amato MP, Battaglia MA, Caputo D et al. (2002) The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. J Neurol 249: 152–163
Kobelt G (2004) Economic evidence in multiple sclerosis: a review. Eur J Health Econ 5: 54–62
Russo P, Capone A, Paolillo A et al. (2004) Cost analysis of relapsing-remitting multiple sclerosis in Italy after the introduction of new disease-modifying agents. Clin Drug Invest 24: 409–420
Lucioni C, Ravasio R, Monti P, Picceo M (2003) I costi della stipsi cronica non organica in pazienti ricoverti in Centri di assistenza per anziani. PharmacoEconomics, Italian Research Articles 5: 69–80 <<Please provide translation>>
Lucioni C, Garancini MP, Massi-Benedetti M, Mazzi S, Serra G (2003) The costs of type 2 diabetes mellitus in Italy. A CODE-2 sub study. Treat Endocrinol 2: 121–133
Lucioni C, Mazzi S, Rossi C (2005) Proton pump inhibitors for the acute treatment of reflux oesophagitis. A cost-effectiveness analysis. Clin Drug Invest 26: 325–336
Acknowledgement
U. Lilja (Stockholm Health Economics, Stockholm, Sweden)
Conflict of interest
No information supplied.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kobelt, G., Berg, J., Lindgren , P. et al. Costs and quality of life of multiple sclerosis in Italy. Eur J Health Econ 7 (Suppl 2), 45–54 (2006). https://doi.org/10.1007/s10198-006-0385-7
Issue Date:
DOI: https://doi.org/10.1007/s10198-006-0385-7